Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Recurrence 1Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Blast Crisis 1

Interventions

nilotinib 50Imatinib Mesylate 48Dasatinib 25bosutinib 18asciminib 17ponatinib 10Homoharringtonine 5Cytarabine 4olverembatinib 3Interferon-alpha 3Decitabine 3tozasertib 2peginterferon alfa-2a 2flumatinib 2fludarabine phosphate 2ON 01910 2Mycophenolic Acid 2Melphalan 2Interferon alpha-2 2Filgrastim 2Cyclophosphamide 2Bone Marrow Transplantation 2BID protein, human 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1troxacitabine 1triciribine 1terameprocol 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × troxacitabine × Clear all
NCT00012259 2021-06-10

Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia

Takeda

Phase 2 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡